NCT01159028View on ClinicalTrials.gov

Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDS

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

March 30, 2017

Study Completion Date

March 30, 2017

Conditions
Recurrent Adult Acute Myeloid LeukemiaAcute Lymphoblastic LeukemiaMyelodysplastic SyndromePh1 Positive CML
Interventions
DRUG

BP1001

Study drug (BP1001) is constituted in normal saline, administered by IV on twice weekly for 28 days.

DRUG

BP1001 in combination with LDAC

Study drug (BP1001) is constituted in normal saline, administered by IV twice weekly for 28 days. Low dose ara-C (LDAC) is self administered twice daily for 10 consecutive days during the 28 day cycle.

Trial Locations (1)

77030

M. D. Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
lead

Bio-Path Holdings, Inc.

INDUSTRY